Notice of Closed Meeting, 75632 [2022-26747]

Download as PDF 75632 Federal Register / Vol. 87, No. 236 / Friday, December 9, 2022 / Notices culvert has been removed and is now daylighted, requiring impacts analysis. • There has been an increase in the proposed usable square feet (USF) for overall building space needed from 42,282 to 80,611, based on the addition of a maintenance building and expansion in the sizes of all other buildings per updated agency requirements. • Stormwater management would be redesigned in the 300-foot section of First Creek due to two new areas of pavement crossing the creek. • The Resolute Paper Mill in Fort Frances, Ontario has since closed and has decreased rail traffic. GSA is preparing an SEIS to assess the potential impacts of these updates, which were not assessed in the 2011 EIS. DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention Notice of Closed Meeting Notice of Closed Meeting GSA has preliminarily identified one action alternative that may be assessed in the SEIS: • Alternative 1: Full Build— Construct the facilities as described in the Preferred Action Alternative assessed in the 2011 EIS and modified by the 2018 project updates. The No Action Alternative will also be considered to satisfy federal requirements for analyzing ‘‘no action’’ under NEPA. Analysis of this alternative will provide a baseline for comparison with impacts from Alternative 1. The SEIS will address the potential environmental impacts of the proposed alternatives on environmental resources including geology and soils, water resources, biological resources, air quality and climate change, noise, traffic and transportation, land use and visual resources, cultural resources, utilities, and human health and safety. The EIS will also address the socioeconomic effects of the project, as well as impacts on environmental justice populations. Impacts may occur from air emissions, noise, and traffic delays associated with construction; as well as soil disturbance from earth moving activities and resultant sedimentation of nearby waterways. Long term benefits to traffic and transportation, air quality, and the local economy are expected from operations of the expanded and modernized LPOE and associated improved traffic flows. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— RFA–OH–22–001, Panel B, Occupational Safety and Health Education and Research Centers (ERC). Dates: February 23–24, 2023. Times: 12:00 p.m.–5:00 p.m. EST. Place: Video-Assisted Meeting. Agenda: To review and evaluate grant applications. For Further Information Contact: Dan Hartley, Ed.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, West Virginia 26505; Telephone: (304) 285– 5812; Email: DHartley@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— DP23–002, Improving Health Outcomes for Patients with Inflammatory Bowel Disease. Date: March 8, 2023. Time: 11:00 a.m.–3:00 p.m., EST. Place: Teleconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Catherine Barrett, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107–3, Atlanta, Georgia 30341–3717; Telephone: (404) 718– 7664; Email: CBarrett@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. William Renner, Director, Facilities Management and Services Programs Division, Great Lakes Region 5, U.S. General Services Administration. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2022–26834 Filed 12–8–22; 8:45 am] [FR Doc. 2022–26749 Filed 12–8–22; 8:45 am] [FR Doc. 2022–26747 Filed 12–8–22; 8:45 am] BILLING CODE 6820–CF–P BILLING CODE 4163–18–P BILLING CODE 4163–18–P lotter on DSK11XQN23PROD with NOTICES1 Alternatives Under Consideration VerDate Sep<11>2014 17:50 Dec 08, 2022 Jkt 259001 PO 00000 Frm 00047 Fmt 4703 Sfmt 9990 E:\FR\FM\09DEN1.SGM 09DEN1

Agencies

[Federal Register Volume 87, Number 236 (Friday, December 9, 2022)]
[Notices]
[Page 75632]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26747]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Strategic 
Business Initiatives Unit, Office of the Chief Operating Officer, CDC, 
pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--DP23-002, Improving Health 
Outcomes for Patients with Inflammatory Bowel Disease.
    Date: March 8, 2023.
    Time: 11:00 a.m.-3:00 p.m., EST.
    Place: Teleconference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Catherine Barrett, Ph.D., 
Scientific Review Officer, National Center for Chronic Disease 
Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop 
S107-3, Atlanta, Georgia 30341-3717; Telephone: (404) 718-7664; Email: 
[email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-26747 Filed 12-8-22; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.